US-based electrocardiogram (ECG) technology developer AliveCor has secured $30m in a series D round co-led by medical device maker Omron Healthcare and medical research company Mayo Clinic.
The round included existing inside investors, according to AliveCor, and although the company did not disclose the identities of those investors, it has received funding from wireless technology provider Qualcomm, Burrill & Company, Khosla Ventures and Oklahoma Life Sciences Fund in the past.
AliveCor is developing mobile ECG technology that uses machine learning to give clinicians rapid information on a patient’s heart rate, using an analysis software platform for early detection of atrial fibrillation, the most common form of cardiac arrhythmia.
Ranndy Kellogg, president and CEO of Omron, said: “Omron Healthcare is excited to expand our strategic partnership with AliveCor. We are establishing new partnerships to redefine the role of technology in heart health as part of our Going for Zero mission.
“Partnering with AliveCor advances our path forward to build robust software programs that play a dynamic role in expanding heart health awareness, transforming the patient and caregiver dynamic and taking real steps toward eliminating heart attack and stroke.”
Qualcomm’s corporate venturing unit, Qualcomm Ventures, Burrill and Oklahoma Life Sciences Fund invested $3m in AliveCor in 2011 before being joined by Khosla for a $10.5m series B round the following year. AliveCor has not revealed details of its series C round.
– Image courtesy of AliveCor, Inc.